Clostridium difficile bacteria, computer illustration. C. difficile is a normal inhabitant of the human intestine, but it can become a pathogen when antibiotics disrupt the normal intestinal flora and ...

I am 78 years old and in fair health.

A recurrence of C. diff is common after an initial episode, with about 20% of people having a recurrence. A recurrence is ...

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides ...

Panelist discusses how recurrent Clostridioides difficile infection results from persistent microbiome disruption, where antibiotic-induced dysbiosis enables bacterial overgrowth and toxin production.

The panelist discusses how recurrent Clostridioides difficile infections involve complex differential diagnosis, including persistent infection, reinfection, and other gastrointestinal conditions.

A person’s biology may play more of a role in how Clostridioides difficile, or C. diff, spreads more so than healthcare facility preventive measures, a new study finds. This means that transmission of ...

A recent Centers for Disease Control and Prevention report found 75 percent of patients in a group of 10,342 cases were already colonized with C. difficile at the time of hospital admission, according ...

New Mexico has the highest rate of Clostridium difficile infections for the second year, while Nevada has the lowest, federal data shows. The measures, developed by the CDC and collected through the ...

Nearly half a million people in the United States suffer from an intestinal infection called Clostridium difficile each year. Approximately half of those individuals become sick enough to require ...

STATEN ISLAND, N.Y., Dec. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule ...

Researchers discovered that men with a history of C. difficile — one of the most common hospital-acquired infections — had lower rates of prostate cancer. The study, published Jan. 30 in Cureus, ...